The summit brought together five leading Nordic life-science companies and over 40 confirmed Asian investors and strategic partners, focusing on partnership and investment opportunities that connect the innovation strengths of the Nordic region with the dynamic capital markets of Asia.

The distinguished panel featured Harry Li, Partner at Eurosin Capital; Dr. Xiaona Jing, Founder of X-bridge Consulting; and Aaron Gu, Partner at Han Kun Law. Together, they shared insights on market dynamics, regulatory changes, and strategic approaches to cross-border transactions in the life sciences industry.

Dr. Xiaona Jing remarked that, “Important deals are often struck over dinner – even major ones. Building trust in the people behind the product or offer is essential when negotiating with a Chinese counterpart.” She added with a touch of humor and confidence, “For those hesitant about entering the Chinese market, my advice is simple: wait too long, and your competitor will make that deal instead of you.”

Aaron Gu drew on his extensive experience advising on some of China’s largest life science transactions, highlighting the country’s expanding role in global capital flows. “China’s pharmaceutical innovation is accelerating, and with a more sophisticated capital market, international collaboration is entering a new phase,” he noted.

From an investor’s perspective, Harry Li of Eurosin Capital discussed the evolving global investment landscape: “China’s influence in the global life sciences industry is growing rapidly. For Nordic companies, this represents tremendous opportunities—but also the need for a deeper understanding of policy, culture, and market risks.”

Moderator Jonas Söderström of BioStock expressed his appreciation to the panel and participants: “We’re seeing increasing interest from Nordic companies in exploring the Chinese market. BioStock is proud to provide a platform that connects innovation, capital, and strategic partnerships across borders.”

One of the panelists concluded, “China is currently the fastest-growing player in the global life sciences sector. Yet, evolving European FDI and IPI regulations, U.S. tariffs, and China’s own internal ‘involution’ dynamics bring both opportunities and challenges. This dialogue is invaluable for fostering mutual understanding and collaboration.”

The forum brought together investors, biotech executives, and policy experts from across Europe and Asia. Through dynamic discussions and exchange of insights, the event underscored the importance of trust, adaptability, and relationship-driven dealmaking in shaping the future of global pharma innovation.